Insider Selling: Beigene Ltd (BGNE) CMO Sells 300 Shares of Stock
Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 300 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $130.12, for a total transaction of $39,036.00. Following the completion of the sale, the chief marketing officer now owns 271,621 shares of the company’s stock, valued at approximately $35,343,324.52. The transaction was disclosed in a filing with the SEC, which is available through this link.
Jane Huang also recently made the following trade(s):
- On Monday, April 8th, Jane Huang sold 14,130 shares of Beigene stock. The stock was sold at an average price of $142.77, for a total transaction of $2,017,340.10.
- On Thursday, March 7th, Jane Huang sold 71 shares of Beigene stock. The stock was sold at an average price of $140.50, for a total transaction of $9,975.50.
- On Monday, March 11th, Jane Huang sold 2,636 shares of Beigene stock. The stock was sold at an average price of $130.28, for a total transaction of $343,418.08.
NASDAQ:BGNE traded down $0.91 on Wednesday, reaching $129.72. 239,844 shares of the company’s stock were exchanged, compared to its average volume of 340,811. The company has a quick ratio of 7.47, a current ratio of 7.52 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $7.76 billion, a PE ratio of -10.68 and a beta of 1.07. Beigene Ltd has a 52 week low of $105.19 and a 52 week high of $220.10.
Several research firms recently weighed in on BGNE. Bank of America began coverage on shares of Beigene in a research report on Friday, March 15th. They set a “buy” rating and a $200.00 price target for the company. BidaskClub lowered shares of Beigene from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Piper Jaffray Companies reduced their price target on shares of Beigene to $170.00 and set an “overweight” rating for the company in a research report on Thursday, February 28th. Maxim Group set a $170.00 price target on shares of Beigene and gave the company a “buy” rating in a research report on Thursday, February 28th. Finally, ValuEngine lowered shares of Beigene from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Beigene presently has an average rating of “Buy” and an average target price of $182.34.
A number of large investors have recently modified their holdings of BGNE. Hillhouse Capital Advisors Ltd. bought a new position in Beigene during the fourth quarter worth about $622,467,000. BlackRock Inc. boosted its position in Beigene by 294.9% during the fourth quarter. BlackRock Inc. now owns 1,877,110 shares of the company’s stock worth $263,281,000 after purchasing an additional 1,401,773 shares during the period. Northern Trust Corp boosted its position in Beigene by 22,043.2% during the fourth quarter. Northern Trust Corp now owns 566,423 shares of the company’s stock worth $79,446,000 after purchasing an additional 563,865 shares during the period. Norges Bank bought a new position in Beigene during the fourth quarter worth about $47,799,000. Finally, Fiera Capital Corp boosted its position in Beigene by 3,554.4% during the fourth quarter. Fiera Capital Corp now owns 215,464 shares of the company’s stock worth $30,221,000 after purchasing an additional 209,568 shares during the period. Hedge funds and other institutional investors own 79.66% of the company’s stock.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.